Getinge reported full-year 2025 organic sales growth of 4.9% and record Q4 performance (Q4 organic +1.2%), with adjusted EBITA for the year SEK 4,880m (margin 14.0%) and Q4 adjusted EBITA SEK 1,809m (margin 17.8%). The group faced >SEK 1bn headwinds from tariffs and currencies but maintained adjusted EBITA margins in line with 2024; adjusted EPS was SEK 11.29 (down from 11.73) and free cash flow fell to SEK 2,652m for the year. Management proposed a dividend of SEK 4.75 per share, flagged continued product momentum (Automatiq launch, regulatory approvals for Rotaflow and iCast, Cardiosave CE reinstatement) and guided organic sales growth of 3–5% for 2026 amid geopolitical uncertainty and some supply/tariff pressures.
Market structure: Getinge (GETI-B) is a direct winner — recurring consumables (ECLS, ventilator) and operating-room equipment should sustain higher-margin annuity revenue; competitors in sterile-reprocessing and operating-table supply (e.g., STERIS, smaller European OEMs) face share pressure from Automatiq and recent regulatory wins. Pricing power is improving (adjusted EBITA margin ex-FX/tariffs 16.0% FY, 20.3% Q4) which implies Getinge can defend margin through price + productivity despite a >SEK1bn FX/tariff headwind. Demand signal: consumables growth (full-year organic 4.9%) points to in-market utilization recovery; Life Science end-market remains lumpy so order volatility will persist. Risk assessment: Tail risks include regulatory reversals (PMA/CE reinstatement rollbacks), major product liability for critical-care devices, or renewed supply-chain delays (Cardiosave shipment pushed to Q2 2026); free cash flow fell ~19% YoY to SEK2,652M which tightens near-term liquidity optionality. Time horizons: immediate (days) — Jan 27 management tone and Q&A; short-term (weeks–months) — Cardiosave component updates and Q1 order patterns; long-term (quarters–years) — 3–5% organic growth guide for 2026 and Automatiq rollout execution. Hidden dependencies: outsized reliance on consumables margin density and key component vendors; tariffs/currency swings >SEK1bn could re-lock margins if FX worsens. Trade implications: Direct — consider establishing a 2–3% long position in GETI-B (European listing) with a 6–12 month horizon targeting +25% upside if margins normalize and Cardiosave ships in Q2 2026; set stop-loss at -12%. Relative value — pair trade long GETI-B vs short STERIS (STE) equal notional for 6–12 months to play product-cycle/automation market-share tailwinds. Options — buy a 9-month call spread on GETI-B (buy ATM, sell +20–25% strike) to cap premium; alternatively sell cash-secured puts ~10–12% OTM if comfortable owning stock. Rotate into European med-techs and trim exposure to global hospital-supply distributors with high FX/tariff sensitivity (reduce weight in distributors by ~2–4%). Contrarian angles: Consensus focuses on headline FCF drop and modest EPS decline but underestimates margin improvement ex-FX/tariffs; the market may over-penalize Getinge given SEK1bn+ transitory headwind — opportunity if FX/tariff trends stabilize. Counterpoint: Automatiq demand is early-stage and adoption could be slow; overreliance on price actions risks losing public-tender share in price-sensitive markets. Historical parallel — device makers with CE reinstatements often take 2–4 quarters to fully ramp; set a 6-month re-evaluation (post-Q2 2026) tied to Cardiosave shipment and net order trends.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.28
